DexCom, Inc. (DXCM)
1 Stock to Buy Near Its 52-Week Low and Hold for 10 Years
This medical device company is down but not out.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why DexCom Stock Flopped on Friday
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth.
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday.
DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises
DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
DexCom Beats Earnings Expectations. Why the Stock Is Trading Lower.
DexCom's U.S. revenue declines 2% in the third quarter from a year earlier.
DexCom Growing Into Its Valuation, But Still No Bargain
DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income, with U.S. revenue down 1.6% but international revenue up 11.8%. Increased competition from Medtronic and Abbott Laboratories, along with slowing growth rates, raises concerns about Dexcom's ability to maintain its market share.
DexCom, Inc. (DXCM) Q3 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q3 2024 Earnings Call Transcript October 24, 2024 4:30 PM ET Company Participants Sean Christensen - VP, Finance and IR Kevin Sayer - President and CEO Jereme Sylvain - CFO Conference Call Participants Danielle Antalffy - UBS Larry Biegelsen - Wells Fargo Matt Taylor - Jefferies Jeff Johnson - Baird Robbie Marcus - JPMorgan Joanne Wuensch - Citibank Michael Polark - Wolfe Research Mathew Blackman - Stifel Travis Steed - Bank of America Marie Thibault - BTIG Matthew O'Brien - Piper Sandler Bill Plovanic - Canaccord Genuity Jayson Bedford - Raymond James Joshua Jennings - TD Cowen Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Mike Kratky - Leerink Partners Steve Lichtman - Oppenheimer Patrick Wood - Morgan Stanley Issie Kirby - Redburn-Atlantic Macauley Kilbane - William Blair Operator Ladies and gentlemen, welcome to the DexCom Third Quarter 2024 Earnings Release Conference Call. My name is Abby, and I will be your operator for today's call.
DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.50 per share a year ago.
Dexcom shares fall on slow revenue growth
Dexcom shares fell on Thursday after the company released third-quarter results that beat expectations but showed slow revenue growth. The company's revenue increased 2% from $975 million a year earlier, according to a release.
Dexcom beats estimates for third-quarter sales, reiterates annual forecast
Medical device maker Dexcom beat Wall Street estimates for third-quarter revenue on Thursday, helped by resilient demand for its continuous glucose monitors for diabetes patients.
